Search Results
Your search for ,WHo matches 20366 pages
Showing 8751 - 8800Atezolizumab for PD-L1–Positive Locally Advanced or Metastatic Triple-Negative Breast Cancer
EARLIER THIS YEAR, atezolizumab was granted accelerated approval in combination with nab-paclitaxel in the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express programmed cell death ligand 1 (PD-L1–stained tumor-infiltrating...
Researchers Examine the Rise in HPV-Related Oropharyngeal Cancers
Human papillomavirus (HPV) causes nearly all cervical cancers and is attributed to some cancers of the vagina, vulva, penis, anus, and oropharynx. Although most HPV infections are asymptomatic and usually resolve within 1 to 2 years, persistent infections can lead to precancer and cancer. According ...
Biosimilar to Trastuzumab in HER2-Overexpressing Breast, Metastatic Breast, and Metastatic Gastric Cancers
Early in 2019, trastuzumab-dttb was approved as a biosimilar to standard trastuzumab for treatment of HER2-expressing breast cancer in the adjuvant setting, metastatic breast cancer, and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior...
Study Shows Benefits of Comprehensive Tobacco Treatment Program
Findings from a large smoking cessation study in patients with cancer indicate comprehensive tobacco treatment is effective in helping individuals successfully quit and abstain from smoking. The prospective study, published by Paul Cinciripini, PhD, Chair of Behavioral Science at the MD Anderson...
Featured Conversations
Developed by Conquer Cancer, the Your Stories podcast series shares unscripted conversations among patients, doctors, and the family and friends who conquer cancer with them. The series also includes transcripts of conversations. In one such featured conversation, “Doctors’ Orders,” two seasoned...
Managing Rectal Cancer: Better Outcomes Now, but Still a Challenging Clinical Setting
The management of rectal cancer has evolved over the past decades, yielding several major practice changes that have substantially improved outcomes. However, rectal cancer treatment remains challenging and even with improved outcomes can result in life-altering morbidity. To shed light on the...
Assessing Full Impact of Prior Authorization Plus Electronic Prior Authorization Needed to Remove Barriers to Care
ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to a proposed rule regarding Secure Electronic Prior Authorization for Medicare Part D. Under the proposal, clinicians would be able to complete prior authorizations for Part D prescriptions online using a ...
New Results From the TAPUR Study Reported in JCO Precision Oncology
New results from ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study demonstrated that single-agent palbociclib has no meaningful clinical activity in patients with CDKN2A-mutated or -deleted advanced pancreatic adenocarcinoma and cholangiocarcinoma. The results, based on data...
Kidney Cancer Association Announces Recipients of Advanced Discovery and Young Investigator Awards
The Kidney Cancer Association has announced the recipients of the Advanced Discovery Awards (ADAs) and Young Investigator Awards (YIAs). In April, the Kidney Cancer Association approved $1.3 million in new grant funding to advance early detection and new treatments of kidney cancer. Established...
Submit Your Research Project Applications for ASCO Research Survey Pool
ASCO’s Center for Research and Analytics (CENTRA) is now accepting research applications from ASCO members who wish to conduct member surveys for research purposes. All researchers who wish to conduct surveys of opted-in ASCO members must complete a Research Survey Pool application. The application ...
Shining Her Light: 2019 International Women Who Conquer Cancer Mentorship Award Recipient Verna Vanderpuye, MBChB
By simply reaching out to new colleagues, Verna Vanderpuye, MBChB, improved the way oncology is practiced across Africa. “It is difficult to find yourself in the [predicament] of low government support, lack of research culture, and inadequate infrastructure,” explained Dr. Vanderpuye, a senior...
Engage, Discuss, and Learn With ASCO eLearning Multidisciplinary Molecular Tumor Boards
The ASCO eLearning Multidisciplinary Molecular Tumor Boards (MMTBs) offer participants an opportunity to learn from experts and from each other on a variety of tumor-based topics. MMTB formats alternate between slide-based and discussion forum-based layouts. The discussion-based MMTBs are an...
Connect With Research Colleagues by Joining the ASCO Research Community Forum Online
The ASCO Research Community Forum (RCF) has created a new online community to provide a venue for physician investigators and research staff who are conducting and managing clinical trials to engage and network, share best practices, access resources, and learn more about the ASCO RCF and its...
ASCO Advocacy and Policy Initiatives/Activities in 2019
Nearly 20% of Americans receive their health insurance coverage through Medicaid. However, unlike Medicare and other payers, Medicaid is not federally required to cover routine care costs, such as physician visits and laboratory studies, for clinical trials. Only 12 states require this coverage,...
Gene Therapy: A March Forward!
GUEST EDITORS Dr. Abutalib is Associate Director, Hematology and Cellular Therapy Program and Director, Clinical Apheresis Program Cancer Treatment at Centers of America, Zion, Illinois; Associate Professor, Rosalind Franklin University of Medicine and Science; and Founder and Co-Editor of...
Multimodal Therapy for High-Risk or Locally Advanced Endometrial Cancer: Is It Any Clearer in 2019?
Endometrial cancer remains the most common gynecologic malignancy affecting women in the United States. There are over 60,000 new cases diagnosed and more than 12,000 deaths annually. Traditional management includes surgical staging, with optimal disease cytoreduction as able, and adjuvant...
Younger, Fit Patients With CLL: Goal Remains Undetectable Minimal Residual Disease and Time-Limited Therapy
As reviewed in this issue of The ASCO Post, Shanafelt and colleagues recently published the interim analysis of E1912, a U.S. Intergroup–led randomized phase III trial comparing ibrutinib/rituximab, followed by ibrutinib to disease progression vs 6 months of fludarabine, cyclophosphamide, and...
Resistance to Immune Checkpoint Blocker May Be Linked to Metabolic Imbalance
A metabolic imbalance in some patients with cancer, following treatment with the checkpoint inhibitor nivolumab, may be associated with resistance to immunotherapy and shorter survival, according to scientists from Dana-Farber Cancer Institute, in collaborative work with the Broad Institute of...
Entrectinib for NTRK-Positive Solid Tumors and ROS1-Positive Lung Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On August 15, 2019, the oral TRK, ROS1, and ALK kinase...
Lisa M. DeAngelis, MD, Named Physician-in-Chief and Chief Medical Officer of Memorial Sloan Kettering
The Memorial Sloan Kettering (MSK) Cancer Center recently announced that Lisa M. DeAngelis, MD, has been named Physician-in-Chief and Chief Medical Officer. An expert in brain cancer, Dr. DeAngelis previously served as Chair of the Department of Neurology and was Co-Founder of MSK’s Brain Tumor...
Cleveland Clinic Appoints Jame Abraham, MD, FACP, as Department Chair of Hematology/Medical Oncology
Jame Abraham, MD, FACP, has been appointed the new Chair of the Hematology/Medical Oncology Department at Cleveland Clinic. In this capacity, he will recruit and develop staff as well as guide the department’s focus on patient access and a multidisciplinary approach to care. Dr. Abraham currently...
Reflecting on My First National Presentation
I gave my first national presentation of my original clinical research on a topic that was to become a professional obsession: finding a cure for esophageal cancer. (Spoiler, I failed.) It was late May 1982. Writing about this now is undoubtedly predicated on my recent retirement, my desire to...
Studies Report Prolonged Long-Term Survival With Immunotherapy vs Chemotherapy in Advanced NSCLC
Longer-term follow-up of patients with advanced non–small cell lung cancer (NSCLC) who are treated with immunotherapy have appreciably extended survival at 5 years, suggesting that for some patients, this disease can be managed as a chronic condition. These findings are based on two presentations ...
Inequities in Care for Patients With Cancer and Serious Mental Illness
Studies show that people suffering from serious mental illness are at increased risk for poor cancer outcomes and mortality due to inequities in their cancer care. Although psychiatric care at the time of diagnosis may improve care, current models for integrating psychiatric interventions and...
Impact of Treating Facility, Provider Volume, and Patient-Sharing in the Treatment of Patients With Multiple Myeloma
A study published by Freeman et al in JNCCN—Journal of the National Comprehensive Cancer Network found that generally, providers with more experience treating multiple myeloma have better outcomes than those with more limited experience. Providers who saw the most cases were more likely to be...
Whole-Brain Radiation Therapy vs Observation After Local Treatment of Melanoma Brain Metastases
In a phase III trial reported in the Journal of Clinical Oncology, Hong et al found that adjuvant whole-brain radiotherapy (WBRT) was not associated with a significant benefit in distant intracranial control vs observation after local treatment of patients with one to three melanoma brain...
High-Dose Chemotherapy vs Standard Chemotherapy and Whole-Lung Irradiation in Ewing Sarcoma With Pulmonary Metastases
As reported in the Journal of Clinical Oncology by Dirksen et al, the R2Pulm trial showed no significant event-free or overall survival benefit with busulfan/melphalan high-dose chemotherapy with autologous stem cell rescue (BuMel) vs standard chemotherapy with whole-lung irradiation in patients...
Association Between Cutaneous Squamous Cell Carcinoma Risk and Indoor Tanning Use in Women
In a Norwegian study published by Lergenmuller et al in JAMA Dermatology, researchers found evidence of a dose-response association between lifetime indoor tanning and risk of development of cutaneous squamous cell carcinoma in women. The association was the same regardless of duration of use and...
Use of Adjuvant Chemotherapy for Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features
In a Children’s Oncology Group study (COG ARET0332) reported in the Journal of Clinical Oncology, Chévez-Barrios et al found discrepancies between central and institutional identification of high-risk features of enucleated unilateral retinoblastoma, and that use of adjuvant chemotherapy based on...
Addition of Doxorubicin to Sorafenib in Advanced Hepatocellular Carcinoma
As reported in JAMA Oncology by Ghassan K. Abou-Alfa, MD, and colleagues, the phase III Alliance/CALGB 80802 trial has shown no progression-free or overall survival benefit with the addition of doxorubicin to sorafenib in patients with advanced hepatocellular carcinoma. The study was stopped early...
How to Help Terminally Ill Patients Find Peace in the Dying Process
End-of-Life Oncology is a new occasional column in The ASCO Post that will explore how to ensure the care received by terminally ill patients is in alignment with their end-of-life goals and wishes. In this inaugural installment, The ASCO Post talked with Lillie D. Shockney, RN, BS, MAS,...
Early Research on Novel Interleukin-12 Gene Therapy in Glioblastoma
Recurrent high-grade glioblastoma has a poor prognosis, with a median overall survival of 6 to 9 months. Treatment is limited, partly because immunotherapy has not yet been shown to be effective in the immunosuppressive microenvironment of this tumor. A novel treatment approach involving...
ESMO 2019: Cabazitaxel vs Abiraterone or Enzalutamide in Previously Treated Metastatic Castration-Resistant Prostate Cancer
As reported at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract LBA13) and simultaneously published in The New England Journal of Medicine by Ronald de Wit, MD, and colleagues, the phase III CARD trial has shown improved imaging-based progression-free survival and overall...
Addition of Ribociclib to Endocrine Therapy in Advanced Breast Cancer: MONALEESA-7
As reported in TheNew England Journal of Medicine by Seock‑Ah Im, MD, PhD, of Seoul National University College of Medicine, and colleagues, an interim analysis in the phase III MONALEESA-7 trial has shown an overall survival benefit with the addition of the cyclin-dependent kinase 4 and 6 (CDK4/6) ...
FDA Pipeline: Advances in Prostate Cancer, Urothelial Cancer, Myelofibrosis, and More
In the past few weeks, the U.S. Food and Drug Administration (FDA) has issued regulatory decisions in prostate cancer, urothelial cancer, myelofibrosis, breast cancer, pediatric brain cancer, leukemia, and skin cancer. Breakthrough Therapy Designation for Niraparib in Metastatic...
Selpercatinib: Precision Medicine for RET Fusion–Positive NSCLC
Selpercatinib (LOXO-292), a RET kinase inhibitor, demonstrated antitumor activity in the lungs and brain and durable responses with acceptable tolerability in patients with RET fusion–positive non–small cell lung cancer (NSCLC), according to an updated analysis of the LIBRETTO-001 registration...
ESMO 2019: Molecular Classification for Adjuvant Treatment in Women With High-Risk Endometrial Cancer
A study by Creutzberg et al investigated the survival outcome of combined adjuvant chemotherapy and radiotherapy vs radiotherapy alone in women with endometrial cancer with high-risk features. The researchers found that 5-year recurrence-free survival varied according to a patient’s specific...
Addition of Ovarian Function Suppression to Ongoing Tamoxifen in Premenopausal Breast Cancer
In a phase III trial reported in the Journal of Clinical Oncology, Kim et al found that the addition of 2 years of ovarian function suppression during ongoing tamoxifen treatment improved disease-free survival vs 5 years of tamoxifen alone in patients with estrogen receptor–positive breast cancer...
Older Sexual and Gender Minorities With Cancer: A Population Hidden in the Open
The term “sexual and gender minorities” encompasses people whose sexual orientation, gender identity and expression, or reproductive development varies from traditional, societal, cultural, or physiologic norms1 and includes lesbian, gay, bisexual, transgender, and queer (LGBTQ) people. More than 3 ...
Expert Point of View: Myung-Ju Ahn, MD, and Roy Herbst, MD, PhD
Formal discussant Myung-Ju Ahn, MD, of Samsung Medical Center Sungkyunkwan University, Seoul, South Korea, said that the CASPIAN results were similar to those of IMpower133, which found that the addition of the immune checkpoint inhibitor atezolizumab to etoposide/carboplatin significantly...
Durvalumab Plus Chemotherapy: New Option for Extensive-Stage SCLC
The addition of the immune checkpoint inhibitor durvalumab to standard therapy significantly improved overall survival vs standard therapy alone for patients with previously untreated extensive-stage small cell lung cancer (SCLC), according to a preplanned interim analysis of the phase III CASPIAN...
Time Without Symptoms or Toxicity After Niraparib Maintenance Therapy in Recurrent Ovarian Cancer
In a study reported in the Journal of Clinical Oncology, Ursula A. Matulonis, MD, and colleagues found that niraparib maintenance therapy was associated with increased time without symptoms or toxicity (TWiST) vs routine surveillance among women with platinum-sensitive recurrent ovarian cancer in...
ESMO 2019: High Conversion Rate With Certain Induction Chemotherapy Regimens Is Associated With Improved Overall Survival in Locally Advanced Pancreatic Cancer
Induction chemotherapy with nab-paclitaxel plus gemcitabine or sequential FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and irinotecan) followed by surgical exploration induced high conversion rates in patients with locally advanced pancreatic cancer, and conversion was associated with...
Greater Consensus From Global Experts on Controversies in Prostate Cancer
In late August, experts from around the globe convened in Basel, Switzerland, at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) to discuss controversial areas related to the management of advanced prostate cancer. Although the full proceedings of the conference will be published in...
ESMO 2019: Personalized Treatment for Head and Neck Cancer Based on Geriatric Assessment
Fit elderly patients aged 70 years and older with head and neck squamous cell carcinoma were able to undergo rigorous treatment that provided benefit similar to that observed in younger patients. However, elderly patients with head and neck squamous cell carcinoma classified by geriatric assessment ...
ESMO 2019: Lenvatinib for Advanced Thymic Carcinoma
Patients with thymic carcinoma that has progressed following treatment with platinum-based chemotherapy may benefit from treatment with lenvatinib, according to findings from a phase II study reported by Itoh et al at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract ...
ESMO 2019: IMvigor130: Addition of Atezolizumab to Platinum-Based Chemotherapy in Advanced Urothelial Carcinoma
Patients with locally advanced or metastatic urothelial carcinoma demonstrated prolonged progression-free survival with the addition of atezolizumab to first-line platinum-based chemotherapy vs treatment with chemotherapy alone, according to phase III data from the IMvigor130 study presented by...
Novel KRAS Inhibitor Shows Activity in Early Study of Advanced Non–Small Cell Lung Cancer
The investigational KRAS inhibitor AMG 510 yielded clinical activity in patients with advanced non–small cell lung cancer (NSCLC), according to updated results of a small ongoing phase I trial reported at the 2019 International Association for the Study of Lung Cancer (IASLC) World Conference on...
Early Research on Novel Interleukin-12 ‘Gene Therapy’ in Glioblastoma
Recurrent high-grade glioblastoma has a poor prognosis, with a median overall survival of 6 to 9 months. Treatment is limited, partly because immunotherapy has not yet been shown to be effective in the immunosuppressive microenvironment of this tumor. A novel treatment approach involving...
Studies Report Prolonged Long-Term Survival With Immunotherapy vs Chemotherapy in Advanced NSCLC
Longer-term follow-up of patients with advanced non–small cell lung cancer (NSCLC) who are treated with immunotherapy have appreciably extended survival at 5 years, suggesting that for some patients, this disease can be managed as a chronic condition. These findings are based on two presentations ...
